Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Oral cholera vaccines and their impact on the global burden of disease.

Wierzba TF.

Hum Vaccin Immunother. 2019;15(6):1294-1301. doi: 10.1080/21645515.2018.1504155. Epub 2018 Oct 12. Review.

2.

When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks?

Clemens J, Holmgren J.

Curr Top Microbiol Immunol. 2014;379:231-58. doi: 10.1007/82_2013_353. Review.

PMID:
24402712
3.

A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.

Baik YO, Choi SK, Olveda RM, Espos RA, Ligsay AD, Montellano MB, Yeam JS, Yang JS, Park JY, Kim DR, Desai SN, Singh AP, Kim IY, Kim CW, Park SN.

Vaccine. 2015 Nov 17;33(46):6360-5. doi: 10.1016/j.vaccine.2015.08.075. Epub 2015 Sep 5.

PMID:
26348402
4.

Improving immunization approaches to cholera.

Saha A, Rosewell A, Hayen A, MacIntyre CR, Qadri F.

Expert Rev Vaccines. 2017 Mar;16(3):235-248. doi: 10.1080/14760584.2017.1249470. Epub 2016 Nov 2. Review.

PMID:
27805467
5.

Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study.

Khatib AM, Ali M, von Seidlein L, Kim DR, Hashim R, Reyburn R, Ley B, Thriemer K, Enwere G, Hutubessy R, Aguado MT, Kieny MP, Lopez AL, Wierzba TF, Ali SM, Saleh AA, Mukhopadhyay AK, Clemens J, Jiddawi MS, Deen J.

Lancet Infect Dis. 2012 Nov;12(11):837-44. doi: 10.1016/S1473-3099(12)70196-2. Epub 2012 Sep 4.

PMID:
22954655
6.

Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis.

Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M, Holmgren J, Clemens JD.

Lancet. 2005 Jul 2-8;366(9479):44-9.

PMID:
15993232
7.

Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis.

Lopez AL, Deen J, Azman AS, Luquero FJ, Kanungo S, Dutta S, von Seidlein L, Sack DA.

Clin Infect Dis. 2018 Jun 1;66(12):1960-1971. doi: 10.1093/cid/cix1039.

8.

Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settings.

Hsiao A, Desai SN, Mogasale V, Excler JL, Digilio L.

Bull World Health Organ. 2017 Apr 1;95(4):303-312. doi: 10.2471/BLT.16.175166. Epub 2017 Feb 21.

9.

A Quantitative Systematic Review and Meta-Analysis of the Effectiveness of Oral Cholera Vaccine as a Reactive Measure in Cholera Outbreaks.

Schwerdtle P, Onekon CK, Recoche K.

Prehosp Disaster Med. 2018 Feb;33(1):2-6. doi: 10.1017/S1049023X17007166. Epub 2018 Jan 10. Review.

PMID:
29317005
10.

Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era.

Desai SN, Pezzoli L, Alberti KP, Martin S, Costa A, Perea W, Legros D.

Hum Vaccin Immunother. 2017 Mar 4;13(3):579-587. doi: 10.1080/21645515.2016.1245250. Review.

11.

Current and future cholera vaccines.

Shaikh H, Lynch J, Kim J, Excler JL.

Vaccine. 2020 Feb 29;38 Suppl 1:A118-A126. doi: 10.1016/j.vaccine.2019.12.011. Epub 2019 Dec 24. Review.

12.

Modeling the effect of water, sanitation, and hygiene and oral cholera vaccine implementation in Haiti.

Fung IC, Fitter DL, Borse RH, Meltzer MI, Tappero JW.

Am J Trop Med Hyg. 2013 Oct;89(4):633-640. doi: 10.4269/ajtmh.13-0201. Erratum in: Am J Trop Med Hyg. 2013 Nov;89(5):1035.

13.

Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.

Charles RC, Hilaire IJ, Mayo-Smith LM, Teng JE, Jerome JG, Franke MF, Saha A, Yu Y, Kováč P, Calderwood SB, Ryan ET, LaRocque RC, Almazor CP, Qadri F, Ivers LC, Harris JB.

PLoS Negl Trop Dis. 2014 May 1;8(5):e2828. doi: 10.1371/journal.pntd.0002828. eCollection 2014 May.

14.

Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort study.

Ali M, Nelson A, Luquero FJ, Azman AS, Debes AK, M'bang'ombe MM, Seyama L, Kachale E, Zuze K, Malichi D, Zulu F, Msyamboza KP, Kabuluzi S, Sack DA.

Lancet Infect Dis. 2017 May;17(5):538-544. doi: 10.1016/S1473-3099(16)30523-0. Epub 2017 Feb 2.

15.

Vibrio cholerae: lessons for mucosal vaccine design.

Bishop AL, Camilli A.

Expert Rev Vaccines. 2011 Jan;10(1):79-94. doi: 10.1586/erv.10.150. Review.

16.

Cholera vaccine: new preventive tool for endemic countries.

Verma R, Khanna P, Chawla S.

Hum Vaccin Immunother. 2012 May;8(5):682-4. doi: 10.4161/hv.19083. Epub 2012 May 1. Review.

PMID:
22634452
17.

Prolonging herd immunity to cholera via vaccination: Accounting for human mobility and waning vaccine effects.

Peak CM, Reilly AL, Azman AS, Buckee CO.

PLoS Negl Trop Dis. 2018 Feb 28;12(2):e0006257. doi: 10.1371/journal.pntd.0006257. eCollection 2018 Feb.

19.

Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India.

Ali M, Sur D, You YA, Kanungo S, Sah B, Manna B, Puri M, Wierzba TF, Donner A, Nair GB, Bhattacharya SK, Dhingra MS, Deen JL, Lopez AL, Clemens J.

Clin Infect Dis. 2013 Apr;56(8):1123-31. doi: 10.1093/cid/cit009. Epub 2013 Jan 29.

PMID:
23362293
20.

Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study.

Franke MF, Ternier R, Jerome JG, Matias WR, Harris JB, Ivers LC.

Lancet Glob Health. 2018 Sep;6(9):e1028-e1035. doi: 10.1016/S2214-109X(18)30284-5.

Supplemental Content

Support Center